Rheumatoid Arthritis
Conditions
Keywords
Rheumatoid arthritis, adalimumab, pharmacokinetic-pharmacodynamic relationship, immunogenicity, Fc gamma receptors polymorphisms
Brief summary
Adalimumab is a fully human monoclonal antibody to tumor necrosis factor-alpha (TNF-α) approved in rheumatoid arthritis (RA) refractory to disease modifying anti rheumatic drugs (DMARDs) and for the treatment of severe, active and progressive RA in adults not previously treated with methotrexate. However, almost one third of patients have no response and approximately 15% develop antibodies towards adalimumab (ATA) after a 6 month course of treatment. There is a relationship between adalimumab concentration and clinical response obtained after 6 month of treatment. Furthermore adalimumab concentration measured 3 months after initiation seems to predict the clinical response at 6 months. There is an important inter individual pharmacokinetic variability of adalimumab. Side effects may occur at the recommended dose and more than 3 months of treatment are generally required to estimate the clinical response. A therapeutic drug monitoring could help clinicians to early adjust the dose to optimize the response and to avoid dose related side effects. To date there is no definite adalimumab target concentration predictive of the clinical response to allow such a pharmacologic monitoring.
Interventions
BIOLOGICALadalimumab
40 mg every two weeks, by subcutaneous way
Sponsors
University Hospital, Tours
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* RA according to the American College of Rheumatology (ACR) 1987 criteria * Treatment with Adalimumab has been chosen by the physician / patient * Treatment given in accordance to the SPC * Stable Disease modifying anti rheumatic drugs (DMARDs) and glucocorticoids 4 weeks before enrollment and during the study period. * Signed consent
Exclusion criteria
* more than one previous treatment with anti TNF-alpha * Past history of malignancy, AIDS * Pregnancy * Change in DMARDS or glucocorticoid dose 4 weeks before entering the study * Active or latent tuberculosis, other active infections * Surgery scheduled during the study period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To characterize the concentration-effect relationship of adalimumab in rheumatoid arthritis | During the 26 weeks of follow up. | The primary objective is to characterize the concentration-effect relationship of adalimumab in rheumatoid arthritis (RA). To this aim, adalimumab concentration on the one hand and clinical and biological markers of disease activity on the other hand will be measured at baseline, week 4, week 8, week 12 and at week 26. Pharmacodynamic (PD) parameters will be estimated using PK(pharmacokinetic)-PD models in which Emax (maximum effect) and EC50 (concentration at which the effect is 50% of the maximum) will describe adalimumab effect on each markers of response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To study the relationship between genetic factors, immunogenicity and response to adalimumab in rheumatoid arthritis | During the 26 weeks of follow up. | The secondary endpoints consist on the association study between FCGR3A polymorphisms, transcriptomic analysis (at baseline), presence of antibodies toward adalimumab (ATA) on the one hand and estimited individuals pharmacodynamic parameters on the other hand. Measurements will be carried out at baseline, week 4, week 8, week 12 and at week 26. |
Countries
France
Outcome results
None listed